It is an ELISA (Enzyme linked immunosorbent assay) based test for semi-quantitative detection of anti-IgG antibodies against SARS-CoV2 virus in human serum and plasma samples.
The kit utilizes recombinant proteins of SARS-CoV2 i.e., Spike 2 and nucleoprotein for detection of anti-COVID antibodies.
The outcome of test result is expressed in as a numerical index value, to indicate the baseline which enables clinicians to study the dynamics of immune response in infected person with respect to time.
It is used as an adjunct to COVID-19 RT-PCR tests to aid in clinical assessment and not for diagnosis.
Individuals typically begin to develop antibodies 1-3 weeks after symptoms begin, so this test will be usually used about 14-21 days following the start of symptoms.